Equities research analysts predict that Codexis, Inc. (NASDAQ:CDXS) will announce ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Codexis’ earnings. The lowest EPS estimate is ($0.06) and the highest is ($0.02). Codexis reported earnings per share of ($0.02) during the same quarter last year, which indicates a negative year over year growth rate of 100%. The firm is scheduled to report its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Codexis will report full-year earnings of ($0.07) per share for the current financial year, with EPS estimates ranging from ($0.13) to ($0.03). For the next financial year, analysts forecast that the business will post earnings of $0.06 per share, with EPS estimates ranging from $0.05 to $0.08. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Codexis.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.09). The company had revenue of $15.58 million for the quarter, compared to analyst estimates of $14.83 million. Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%.

A number of analysts recently weighed in on CDXS shares. ValuEngine lowered shares of Codexis from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 4th. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 5th. Craig Hallum upped their target price on shares of Codexis from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 27th. HC Wainwright upped their target price on shares of Codexis to $22.50 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, Zacks Investment Research lowered shares of Codexis from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $21.07.

NASDAQ:CDXS traded down $0.17 on Monday, reaching $17.93. 363,142 shares of the company’s stock were exchanged, compared to its average volume of 383,701. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.42 and a quick ratio of 3.38. Codexis has a 52-week low of $12.85 and a 52-week high of $23.05. The firm has a market capitalization of $985.54 million, a PE ratio of -85.38 and a beta of -0.15.

In related news, SVP James Lalonde sold 19,999 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $18.65, for a total value of $372,981.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gordon Sangster sold 80,000 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $20.88, for a total value of $1,670,400.00. Following the completion of the transaction, the chief financial officer now directly owns 174,453 shares of the company’s stock, valued at $3,642,578.64. The disclosure for this sale can be found here. Insiders have sold 155,071 shares of company stock worth $3,190,531 over the last 90 days. Insiders own 10.70% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in CDXS. Quantamental Technologies LLC acquired a new stake in shares of Codexis in the fourth quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Codexis by 152.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 1,711 shares during the period. NumerixS Investment Technologies Inc acquired a new stake in shares of Codexis in the first quarter valued at approximately $66,000. Advisor Group Inc. boosted its holdings in shares of Codexis by 184.2% in the first quarter. Advisor Group Inc. now owns 3,342 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 2,166 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Codexis by 236.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,375 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 3,075 shares during the period. 85.51% of the stock is owned by hedge funds and other institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Story: Outstanding Shares

Get a free copy of the Zacks research report on Codexis (CDXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.